CVS Caremark and Zepbound: Coverage Is Back, but Check Your Plan

Zepbound is covered again on CVS Caremark’s most common commercial formularies. CVS added it back “as an additional preferred option” on October 1, 2026, alongside Wegovy, which ended the exclusion that began on July 1, 2025.^[1][2] That does not mean your plan covers it. The change applies to employers and health plans that use Caremark’s template formularies and choose to cover weight-loss drugs at all, and CVS says those sponsors “retain discretion to customize coverage.”^[2] Lilly’s own wording is “select CVS Caremark formularies.”^[3] So the first step is to check your own plan, not the headline. If your plan still leaves Zepbound out, you have three routes: a formulary exception backed by your prescriber, cash through LillyDirect from $299 a month, or a switch to Wegovy, which produced less weight loss than Zepbound in the one head-to-head trial.^[4][7]

What happened, in order

CVS framed both moves as price negotiations. In 2025 it said preferring Wegovy would allow “wider, more affordable coverage.”^[1] In 2026 it said negotiations with drug makers had secured a lower cost that let it “expand options.”^[2] Neither statement gives a price. The rebates and net prices behind a formulary decision are not public, so it is not possible to say from the outside how much either drug costs the plan.

The New York lawsuit, Larkin v. Caremark Rx, remained open in October 2026. The patients’ arguments are claims, not findings. The court has not ruled on whether removing Zepbound was lawful.^[13][14]

What “back on the formulary” does and does not mean

A pharmacy benefit manager like Caremark builds a default drug list, called a template formulary. The employer, union or health plan that hires Caremark, called the plan sponsor, decides whether to adopt it and what to change. The October change edits the template. It reaches you only if your sponsor uses that template, keeps the change, and covers weight-loss drugs in the first place.^[2]

• Some plans never removed Zepbound. A sponsor with a custom formulary could keep it throughout. Those members saw no change in either direction.
• Some plans exclude all weight-loss drugs. If your plan does not cover Wegovy for weight either, the October change does nothing for you. That is an exclusion of the whole category, and no clinical appeal overturns it. Our guide to getting a GLP‑1 covered explains the difference between a denial and an exclusion.
• Preferred does not mean automatic. CVS’s 2026 statement says nothing about prior authorization. Expect your plan’s usual criteria, typically a BMI threshold, to apply to Zepbound as they apply to Wegovy.^[2]
• Medicare is separate. The announcement covers Caremark’s commercial formularies.^[2] Medicare Part D enrollees reach Zepbound for weight through the federal Medicare GLP‑1 Bridge, which covers the KwikPen prescribed for weight management for those who qualify.^[4]

If your plan does cover Zepbound, Lilly’s savings card can bring the pharmacy cost down to as little as $25 for a fill, with savings capped at $100 a month and $1,300 a year. The card is for commercial insurance only, excludes government programs, and expires on December 31, 2026.^[3]

How to find out where your plan stands

1. Ask Caremark about your own plan. Sign in at Caremark.com or call the member number on the back of your ID card, and ask whether Zepbound is covered, preferred or non-formulary on your plan and what you would pay.^[1] That answer outranks any news report.
2. Ask your HR or benefits office two questions. Does our plan cover GLP‑1 drugs for weight management? Did we adopt Caremark’s October 1 formulary change for Zepbound? Self-funded employers make these choices themselves.
3. If a claim was denied, read the reason on the notice. “Not on formulary” or “excluded” is a different problem from “criteria not met”, and it takes a different fix. Our guide to prior authorization and appeals walks through each denial type.
4. Ask again at open enrollment. Sponsors can revisit what they cover, so a plan that kept Zepbound off this year may not next year.

If your plan still excludes Zepbound

Ask for a formulary exception

During the exclusion, CVS published the route itself. A member who had tried Wegovy and “either experienced severe or intolerable side effects or did not achieve sufficient weight loss” could request a formulary exception, which gets “a case-by-case medical necessity review” and needs supporting records from the prescriber.^[1] That was written for the 2025 exclusion, and your plan’s current criteria may differ, but the logic holds: an exception asks for a drug the plan leaves out because the covered alternative failed or cannot be used. The strongest requests document what happened on Wegovy, with dates, doses and side effects.

One clinical difference matters here. The FDA has cleared Zepbound for adults with obesity who have moderate or severe obstructive sleep apnea; Wegovy carries no such approval.^[5][6] For someone with diagnosed sleep apnea, that is a reason for Zepbound that is not about weight, and some plans review it under different rules. Our article on Zepbound for sleep apnea covers what the trials showed.

Federal rules set the clock for some plans. A plan that must cover essential health benefits, which means most individual and small-group plans, has to decide a standard exception request within 72 hours and an urgent one within 24 hours. Being partway through treatment on a non-formulary drug counts as grounds for the faster review, and a denied exception can go to an independent reviewer.^[10] Large employer plans and self-funded plans are not bound by that rule and set their own process.

Appeal a denial

If the exception is denied, you have 180 days from the notice to file an internal appeal. If that fails, you have four months to ask for an external review, which is decided within 45 days, or 72 hours when urgent.^[11][12] Your prescriber can write the letter; our prior authorization letter generator drafts one from your details.

Paying cash through LillyDirect

Lilly sells Zepbound directly to self-paying patients in two forms: a single-dose vial, sold only through LillyDirect, and a multi-dose KwikPen. Both cost the same.^[4] People whose commercial plan does not cover the KwikPen can use Lilly’s card to pay the same $299 and $399 for the two lowest doses at other pharmacies.^[3]

The $449 rate on the higher doses depends on refilling within 45 days of the last delivery. Miss that window and the 10 to 15 mg doses cost $699.^[3][4] The federal TrumpRx site lists the same Zepbound prices and sends buyers to LillyDirect; our TrumpRx price check compares it with every other route, and the Zepbound cost page keeps the current figures. For a ranking of every cash option, see the cheapest GLP‑1 without insurance.

You still need a prescriber, and telehealth sellers handle the cash route in two ways. Some write the prescription and leave the drug bill to someone else: Brightmeds charges a consult fee for Zepbound vial prescriptions with LillyDirect billing the drug, Wisp charges a consult fee while your pharmacy bills the Zepbound, and Heva Health charges a monthly care fee with the drug billed separately. Corsica Health runs a prescription-only service of the same kind, with the drug bought from the maker.

Others sell Zepbound inside their own price. HeliMeds sells it in four-week orders paid up front, WellMedRx on a month-to-month plan, and WePeptideRx as a 28-day supply at any strength. Noom includes brand tirzepatide among the options in its GLP-1Rx program. Before choosing one of these, compare its figure, and what it includes, with the LillyDirect table above.

Switching to Wegovy: what the evidence says

Moving to Wegovy was the route CVS offered when it removed Zepbound, and anyone on a plan that still prefers only Wegovy may face the same choice. CVS said members with an active Zepbound prior authorization would not need a new one to move.^[1]

On average, expect less weight loss. In SURMOUNT‑5, the only randomized head-to-head trial in people with obesity and without diabetes, 751 adults took the highest dose they could tolerate of either drug for 72 weeks. Weight fell 20.2% on tirzepatide (Zepbound) and 13.7% on semaglutide (Wegovy), and waist size fell 18.4 cm against 13.0 cm.^[7] The trial was open-label and funded by Lilly, but the gap was large and consistent across every weight-loss threshold measured.

Neither label offers a way to convert one dose into the other. Wegovy starts at 0.25 mg a week and rises every four weeks to a usual 2.4 mg; Zepbound starts at 2.5 mg and rises in 2.5 mg steps.^[5][6] A modeling study, funded by Novo Nordisk and built from trials in people with type 2 diabetes, estimated that Wegovy 2.4 mg most closely matches tirzepatide 10 mg, and that lower semaglutide doses do not match higher tirzepatide doses.^[8] That is an estimate of average weight loss, not a dosing instruction. Where you restart is your prescriber’s call; our article on switching between GLP‑1 drugs explains why most switches start near the bottom of the new drug’s dose schedule.

The closest real-world parallel to a forced switch comes from the UK, where Lilly raised the tirzepatide price in September 2025. Among more than a million self-paying patients at one telehealth service, the share of patients moving off tirzepatide onto semaglutide went up 9.26 percentage points after the increase and then eased. At 12 months, estimated weight loss was 19.9% on tirzepatide and 16.4% on semaglutide.^[9] Those groups were not randomized, the semaglutide group was small, and several authors work for the provider, so the figures describe that population rather than predict an individual result.

If you pay cash and a switch is on the table, a seller that stocks more than one brand can save a second intake. Vital Edge lists brand Wegovy, Ozempic and Mounjaro, the diabetes-labeled form of tirzepatide, next to its compounded plans.